Relief Therapeutics Holding SA announced that its current chief executive officer (CEO), Jack Weinstein, will be stepping down as part of a leadership transition. The company is announced that Michelle Lock, a highly experienced pharmaceutical executive and current independent member of the company's board of directors, will be assuming the role of CEO on an interim basis. Ms. Lock previously held executive roles as chief operating officer of Covis Pharma Group and senior vice president and head of Europe and International at Acceleron Pharma Inc. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience and spent 24 years with Bristol-Myers Squibb.

Her appointment as interim CEO of Relief is effective immediately.